Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics Limited has announced that its Annual General Meeting for the financial year ending 31 March 2025 will be held on 27 August 2025. This meeting is significant for stakeholders as it includes the election of Directors, with nominations due by 9 July 2025, potentially impacting the company’s strategic direction and governance.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 5,025,547
Technical Sentiment Signal: Buy
Current Market Cap: A$91.17M
Learn more about ATX stock on TipRanks’ Stock Analysis page.